Original Paper

CFH Gene Variant, Y402H, and Smoking, Body Mass Index, Environmental Associations with Advanced Age-Related Macular Degeneration
Johanna M. Seddon^{a, b}, Sarah George^a, Bernard Rosner^c, Michael L. Klein<sup>d

a</sup>Epidemiology Unit, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School,
^bDepartment of Epidemiology, and
^cChanning Laboratory, Harvard Medical School, Boston, Mass.,
^dDevers Eye Institute, Macular Degeneration Center, Casey Eye Institute, Oregon Health and Science University, Portland, Oreg., USA

Address of Corresponding Author

Hum Hered 2006;61:157-165 (DOI: 10.1159/000094141)

  Key Words

• Case-control association analysis
• Environmental risk factor
• Epidemiologic approaches
• Gene-environment interaction
• Genotype
• Macular degeneration

  Abstract

Objectives: We tested the hypothesis that modifiable lifestyle factors alter the genetic susceptibility associated with a common coding variant in the complement factor H (CFH) gene, Y402H, for the leading cause of blindness among the elderly, age-related macular degeneration (AMD). Methods: In this case-control association analysis, Caucasian participants in the multicenter Age-Related Eye Disease Study with advanced AMD (n = 574 cases) or no AMD (n = 280 controls) were evaluated. AMD status was determined by grading of fundus photographs. Risk factors including cigarette smoking and body mass index (BMI) were assessed and DNA specimens were genotyped for the variant in the CFH gene. Unconditional logistic regression analyses were performed. Attributable risks and multivariable AMD risk scores were calculated. Results: The number of risk alleles for Y402H was associated with advanced AMD, with odds ratios (OR) of 2.7 (95% confidence interval (CI) 1.8-3.8) for the CT heterozygous genotype and OR 7.4 (4.7-11.8) for the homozygous CC risk genotype, after controlling for demographic and behavioral risk factors. Current cigarette smoking (OR 5.1) and high BMI 30 (OR 2.1) were independently related to AMD, controlling for genotype. The association between AMD and BMI varied dependent on genotype (P interaction = 0.006 for the CT vs. TT genotype). The CC genotype plus higher BMI (OR 5.9) or smoking (OR 10.2) conferred the greatest risks. Gene plus environment risk scores provided an area under the receiver operating characteristic (ROC) curve of 0.70-0.75. Conclusions: Genetic and environmental factors are independently related to advanced AMD, and modifiable factors alter genetic susceptibility. The AMD risk score identifies a highly susceptible population.

Copyright © 2006 S. Karger AG, Basel

  References

1.

Seddon JM, Cote J, Page WF, Aggen S, Neale M: The US twin study of age-related macular degeneration: Relative roles of genetic and environmental influences. Arch Ophthalmol 2005;123:321-327.

2.

Seddon JM, Hankinson S, Speizer F, Willett WC: A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276:1141-1146.

3.

Tomany SC, Wang JJ, van Leeuwen R, et al: Risk factors for incident age-related macular degeneration. Pooled findings from 3 continents. Ophthalmol 2004;111:1280-1287.

4.

Seddon JM, Cote J, Davis N, Rosner B: Progression of age-related macular degeneration: Association with body mass index, waist circumference and waist-hip ratio. Arch Ophthalmol 2003;124.

5.

Age-related Eye Disease Study Group: Risk factors associated with age-related macular degeneration. A case-control study in the Age-related Eye Disease Study. Ophthalmol 2000;107:2224-2232.

6.

Seddon JM, Ajani UA, Sperduto RD, et al: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 1994;272:1413-1420.

7.

Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C & E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417-1436.

8.

van Leeuwen R, Boekhoorn S, Vingerling JR, et al: Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005;294:3101-3107.

9.

Cho E, Seddon J, Rosner B, et al: Prospective study of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 2004;122:883-892.

10.

Seddon JM, Ajani UA, Mitchell BD: Familial aggregation of age-related maculopathy. Am J Ophthalmol 1997;123:199-206.

11.

Klaver CC, Wolfs RC, Assink JJ, et al: Genetic risk of age-related maculopathy: Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646-1651.

12.

Seddon JM, Santangelo SL, Book K, et al: A genomewide scan for age-related macular degenerations providences evidence for linkage to several chromosomal regions. Am J Hum Genet 2003;73:780-790.

13.

Majewski J, Schultz DW, Weleber RG, et al: Age-related macular degeneration- A genome scan in extended families. Am J Hum Genet 2003;73:540-550.

14.

Schick JH, Iyengar SK, Klein BE, et al: A whole-genome screen of a quantitative trait of age-related maculopathy in sibships from the Beaver Dam Eye study. Am J Hum Genet 2003;72:1412-1424.

15.

Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA: Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-424.

16.

Klein RJ, Zeiss C, Chew E, et al: Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389.

17.

Haines JL, Hauser MA, Schmidt S, et al: Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421.

18.

Hageman GS, Anderson DH, Johnson LV, et al: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. PNAS 2005;102:7227-7232.

19.

Zareparsi S, Branham KE, Li M, et al: Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005;149-153.

20.

Souied EH, Leveziel N, Richard F, et al: Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis 2005;11:1135-1140.

21.

Magnusson KP, Duan S, Sigurdsson H, et al: CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoSMed 2006;3:109-114.

22.

Seddon JM, Sharma S, Adelman RA: Evaluation of the clinical age-related maculopathy staging system. Ophthalmol 2006;113:260-266.

23.

Seddon JM, Samelson LJ, Page WF, Neale MC: Twin study of macular degeneration: methodology and application to genetic epidemiologic studies. Invest Ophthalmol Vis Sci 1997; 38:S676.

24.

Rosner B: Fundamentals of Biostatistics. 6th Edition. Boston: Duxbury Press, 2005.

25.

Hanley JA, McNeil BJ: The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.

26.

Sepp T, Kahn JC, Thurlby DA, et al: Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascualrization in smokers and nonsmokers. Invest Ophthalmol Vis Sci 2006;47:536-540.

27.

Schmidt A, Hauser MA, Scott WK, et al: Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Gen 2006;78:852-864.

28.

D'Agostino RB, Grundy S, Sullivan LM, Wilson P, for the CHD Risk Prediction Group: Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286:180-187.

29.

Seddon JM, George S, Rosner B: Cigarette smoking, fish and omega-3 fatty acid intake are associated with age-related macular degeneration: The U.S. twin study of age-related macular degeneration, Arch Ophthalmol 2006, in press, July.

30.

Anderson DH, Mullins RF, Hageman GS, Johnson LV: Perspective: A role of local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-431.

31.

Seddon JM, Gensler G, Milton R, Klein M, Rifai N: Association between C-reactive protein and age-related macular degeneration. JAMA 2004;291:704-710.

32.

Seddon JM, George S, Rosner B: Progression of age-related macular degeneration: Prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005;123:774-782.

33.

Seddon JM, Gensler G, Klein ML, Milton RC: C-reactive protein and homocysteine are associated with dietary and behavioral risk factors for age-related macular degeneration. Nutrition 2006;22:441-443.

34.

DeLa Paz M, Pericak-Vance MA, Haines JL, Seddon JM: Phenotypic heterogeneity in families with age-related macular degeneration. Am J Ophthalmol 1997;124:331-343.

35.

Smith GD, Lewis ES, Hansell AL, Palmer LJ, Burton PR: Genetic epidemiology and public health: Hope, hype, and future prospects. Lancet 2005;366:1484-1498.

  Author Contacts

Johanna M. Seddon, MD, ScM
Epidemiology Unit, Massachusetts Eye and Ear Infirmary
243 Charles St.
Boston, MA 02114 (USA)
Tel. +1 617 573 4011, Fax +1 617 573 4021, E-Mail Johanna_Seddon@meei.harvard.edu

  Article Information

Received: April 13, 2006
Accepted: April, 14, 2006
Published online: June 30, 2006
Number of Print Pages : 9
Number of Figures : 0, Number of Tables : 3, Number of References : 35

  Publication Details

Human Heredity (International Journal of Human and Medical Genetics)

Vol. 61, No. 3, Year 2006 (Cover Date: August 2006)

Journal Editor: Devoto, M. (Philadelphia, Pa.)
ISSN: 0001-5652 (print), 1423-0062 (Online)

For additional information: http://www.karger.com/HHE

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.